Risk Factors for Adverse Outcomes of Endovascular Revascularization in Lower Extremity Arteriosclerosis Occlusion

Launched by FIRST AFFILIATED HOSPITAL XI'AN JIAOTONG UNIVERSITY · Oct 18, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the risk factors that can lead to poor outcomes after a specific treatment called endovascular revascularization for patients with a condition known as lower extremity arteriosclerosis obliterans (ASO). ASO is a common disease that affects blood flow to the legs, causing symptoms like pain and discomfort. The goal of the study is to better understand what makes some patients more likely to experience complications after this treatment, which could help doctors improve care and outcomes for future patients.

To participate in this study, individuals must be adults who have received successful endovascular revascularization for their lower extremity ASO, and their medical information must be complete. Those with serious infections, tumors, or other significant health issues will not be included. Participants will be followed for one to three years after the procedure, during which researchers will check for any heart or leg-related problems and overall health. This research is important because it aims to identify ways to prevent complications and enhance the quality of life for patients suffering from this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with lower extremity arterial occlusive disease who underwent successful endovascular revascularization.
• • Preoperative baseline clinical data were complete.
• • Patients who completed the informed consent form.
• Exclusion Criteria:
• • Patients with severe infections, tumors, liver and kidney failure, and autoimmune diseases.
• • Patients with incomplete baseline data.
• • Patients lost to follow-up.